<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578938</url>
  </required_header>
  <id_info>
    <org_study_id>MOD19100041-005</org_study_id>
    <secondary_id>R01MH124983</secondary_id>
    <nct_id>NCT04578938</nct_id>
  </id_info>
  <brief_title>Ketamine + Cognitive Training for Suicidality in the Medical Setting</brief_title>
  <official_title>Ketamine + Cognitive Training for Suicidality in the Medical Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rebecca Price</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project seeks to identify the acute and longer-term impact of a single dose of&#xD;
      intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in&#xD;
      the medical inpatient setting. The investigators will then test whether ketamine's rapid&#xD;
      effects can be extended by introducing helpful information delivered by a computer-based&#xD;
      training protocol. This work could ultimately lead to the ability to treat suicidality more&#xD;
      efficiently and with broader dissemination by rapidly priming the brain for helpful forms of&#xD;
      learning.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">March 2, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale for Suicide Ideation</measure>
    <time_frame>infusion +24 hours (1 day)</time_frame>
    <description>suicidal ideation/thoughts; range 0-38; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale for Suicide Ideation</measure>
    <time_frame>infusion +5 days (4 days)</time_frame>
    <description>suicidal ideation/thoughts; range 0-38; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale for Suicide Ideation</measure>
    <time_frame>infusion +12 days (7 days)</time_frame>
    <description>suicidal ideation/thoughts; range 0-38; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale for Suicide Ideation</measure>
    <time_frame>infusion +1 month (2 weeks)</time_frame>
    <description>suicidal ideation/thoughts; range 0-38; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale for Suicide Ideation</measure>
    <time_frame>infusion +3 months (2 months)</time_frame>
    <description>suicidal ideation/thoughts; range 0-38; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale for Suicide Ideation</measure>
    <time_frame>infusion +6 months (3 months)</time_frame>
    <description>suicidal ideation/thoughts; range 0-38; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale for Suicide Ideation</measure>
    <time_frame>infusion +9 months (3 months)</time_frame>
    <description>suicidal ideation/thoughts; range 0-38; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale for Suicide Ideation</measure>
    <time_frame>infusion +12 months (3 months)</time_frame>
    <description>suicidal ideation/thoughts; range 0-38; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal behaviors: medical chart review</measure>
    <time_frame>infusion +12 months (12 months)</time_frame>
    <description># of patients with occurrence of any suicidal act (derived from medical chart) including: re-attempt, re-hospitalization for suicidality, or completed suicide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Suicidal behaviors: Columbia Suicide Severity Rating Scale (CSSRS)</measure>
    <time_frame>infusion +12 months (12 months)</time_frame>
    <description># of patients with occurrence of any suicidal act (derived from CSSRS, each item is scored yes/no for period since last assessment) including: re-attempt, re-hospitalization for suicidality, or completed suicide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>infusion +24 hours (1 day)</time_frame>
    <description>depression severity; range 0-60; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>infusion +5 days (4 days)</time_frame>
    <description>depression severity; range 0-60; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>infusion +12 days (7 days)</time_frame>
    <description>depression severity; range 0-60; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>infusion +1 month (1 week)</time_frame>
    <description>depression severity; range 0-60; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>infusion +3 months (1 week)</time_frame>
    <description>depression severity; range 0-60; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>infusion +6 months (1 week)</time_frame>
    <description>depression severity; range 0-60; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>infusion +9 months (1 week)</time_frame>
    <description>depression severity; range 0-60; high score=worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>infusion +12 months (1 week)</time_frame>
    <description>depression severity; range 0-60; high score=worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adult Suicide Ideation Questionnaire</measure>
    <time_frame>infusion +24 hours (1 day)</time_frame>
    <description>suicidal ideation/thoughts; range 0-150; high score=worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Suicide Ideation Questionnaire</measure>
    <time_frame>infusion +5 days (4 days)</time_frame>
    <description>suicidal ideation/thoughts; range 0-150; high score=worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Suicide Ideation Questionnaire</measure>
    <time_frame>infusion +12 days (7 days)</time_frame>
    <description>suicidal ideation/thoughts; range 0-150; high score=worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Suicide Ideation Questionnaire</measure>
    <time_frame>infusion +1 month (2 weeks)</time_frame>
    <description>suicidal ideation/thoughts; range 0-150; high score=worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Suicide Ideation Questionnaire</measure>
    <time_frame>infusion +3 months (2 months)</time_frame>
    <description>suicidal ideation/thoughts; range 0-150; high score=worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Suicide Ideation Questionnaire</measure>
    <time_frame>infusion +6 months (3 months)</time_frame>
    <description>suicidal ideation/thoughts; range 0-150; high score=worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Suicide Ideation Questionnaire</measure>
    <time_frame>infusion +9 months (3 months)</time_frame>
    <description>suicidal ideation/thoughts; range 0-150; high score=worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms</measure>
    <time_frame>infusion +24 hours (1 day)</time_frame>
    <description>Self-reported depression (range: 0-27; higher scores = worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms</measure>
    <time_frame>infusion +5 days (4 days)</time_frame>
    <description>Self-reported depression (range: 0-27; higher scores = worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms</measure>
    <time_frame>infusion +12 days (7 days)</time_frame>
    <description>Self-reported depression (range: 0-27; higher scores = worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms</measure>
    <time_frame>infusion +1 month (1 week)</time_frame>
    <description>Self-reported depression (range: 0-27; higher scores = worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms</measure>
    <time_frame>infusion +3 months (1 week)</time_frame>
    <description>Self-reported depression (range: 0-27; higher scores = worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms</measure>
    <time_frame>infusion +6 months (1 week)</time_frame>
    <description>Self-reported depression (range: 0-27; higher scores = worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms</measure>
    <time_frame>infusion +9 months (1 week)</time_frame>
    <description>Self-reported depression (range: 0-27; higher scores = worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms</measure>
    <time_frame>infusion +12 months (1 week)</time_frame>
    <description>Self-reported depression (range: 0-27; higher scores = worse outcome)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Implicit Association Test</measure>
    <time_frame>infusion +24 hours (1 day)</time_frame>
    <description>performance-based &quot;target engagement&quot; measure of suicidal cognition; range = -inf-inf; high score=worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Implicit Association Test</measure>
    <time_frame>infusion +5 days (4 days)</time_frame>
    <description>performance-based &quot;target engagement&quot; measure of suicidal cognition; range = -inf-inf; high score=worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Implicit Association Test</measure>
    <time_frame>infusion +12 days (7 days)</time_frame>
    <description>performance-based &quot;target engagement&quot; measure of suicidal cognition; range = -inf-inf; high score=worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Implicit Association Test</measure>
    <time_frame>infusion +1 month (2 weeks)</time_frame>
    <description>performance-based &quot;target engagement&quot; measure of suicidal cognition; range = -inf-inf; high score=worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Implicit Association Test</measure>
    <time_frame>infusion +3 month (2 months)</time_frame>
    <description>performance-based &quot;target engagement&quot; measure of suicidal cognition; range = -inf-inf; high score=worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Implicit Association Test</measure>
    <time_frame>infusion +6 month (3 months)</time_frame>
    <description>performance-based &quot;target engagement&quot; measure of suicidal cognition; range = -inf-inf; high score=worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Implicit Association Test</measure>
    <time_frame>infusion +9 month (3 months)</time_frame>
    <description>performance-based &quot;target engagement&quot; measure of suicidal cognition; range = -inf-inf; high score=worse outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Implicit Association Test</measure>
    <time_frame>infusion +12 month (3 months)</time_frame>
    <description>performance-based &quot;target engagement&quot; measure of suicidal cognition; range = -inf-inf; high score=worse outcome</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Suicide, Attempted</condition>
  <arm_group>
    <arm_group_label>Ketamine + Cognitive Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine + Sham Training</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No-infusion (TAU) + Cognitive Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No-infusion (TAU) + Sham Training</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ketamine</intervention_name>
    <description>Single subanesthetic infusion of ketamine (0.5mg/kg)</description>
    <arm_group_label>Ketamine + Cognitive Training</arm_group_label>
    <arm_group_label>Ketamine + Sham Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive training</intervention_name>
    <description>8 sessions of computer-based cognitive training</description>
    <arm_group_label>Ketamine + Cognitive Training</arm_group_label>
    <arm_group_label>No-infusion (TAU) + Cognitive Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sham Training</intervention_name>
    <description>8 sessions of computer-based sham training</description>
    <arm_group_label>Ketamine + Sham Training</arm_group_label>
    <arm_group_label>No-infusion (TAU) + Sham Training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants who receive ketamine will:&#xD;
&#xD;
          1. be between the ages of 18 and 65 years&#xD;
&#xD;
          2. be a medical inpatient referred for psychiatric consultation/liaison due to&#xD;
             suicidality and determined by psychiatric C/L to require inpatient psychiatric&#xD;
             hospitalization&#xD;
&#xD;
          3. possess a level of judgment and understanding sufficient to agree to all procedures&#xD;
             required by the protocol and must sign an informed consent document&#xD;
&#xD;
          4. be deemed an appropriate and reasonable medical candidate for intravenous ketamine by&#xD;
             a physician authorized to prescribe medication to the patient during inpatient&#xD;
             hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of current/acute psychosis, mania, delirium, or dementia, or a diagnosis of&#xD;
             developmental disorder with significant language and/or intellectual impairment&#xD;
&#xD;
          2. Mini-Mental State Exam (MMSE) &lt; 23&#xD;
&#xD;
          3. Current pregnancy or breastfeeding&#xD;
&#xD;
          4. Reading level &lt;5th grade as per WRAT-3 reading subtest AND patient declines to have&#xD;
             all questionnaire items and task instructions read aloud to them at all assessment&#xD;
             points&#xD;
&#xD;
          5. Past intolerance or hypersensitivity to ketamine or esketamine&#xD;
&#xD;
          6. Patients taking St John's Wort&#xD;
&#xD;
          7. Patients who have received ECT in the past 6 months prior to intake&#xD;
&#xD;
          8. Patients at ongoing risk for severe substance or alcohol withdrawal related issues&#xD;
             (e.g., delirium tremens, severe opiate withdrawal) or who present with&#xD;
             substance-induced psychosis&#xD;
&#xD;
          9. Patients who, based on expressed preference and/or home geographic location, are&#xD;
             deemed by the Psychiatric Consultation/Liaison service to be likely to receive&#xD;
             inpatient psychiatric hospitalization at an alternate location outside of Western&#xD;
             Psychiatric Institute &amp; Clinic&#xD;
&#xD;
         10. Arrested individuals brought in by the legal system for medical stabilization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca B Price, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Rebecca Price</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry and Psychology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suicide</mesh_term>
    <mesh_term>Suicide, Attempted</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

